Skip to content
Screener

Haemonetics HAE Q3 2026 earnings

Reported February 5, 2026 · Before market open

Revenue$339.0MBeat by $7.1M
EPS$1.31Beat by $0.04
Revenue estimate$331.9M
EPS estimate$1.27

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$345.0M
EPS estimate$1.30

Financials

Q3 2026

Income statement

See full
Revenue$339.0M-2.7%
Gross profit$202.4M+4.6%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$363.4M+13.3%
Total debt$1.2B0.0%
Total equity$911.5M+0.5%
Total assets$2.5B-1.6%

Cash flow

See full
Operating cash flow$93.6M+114%
CapEx$6.3M-25.7%
Free cash flow$87.2M+148%

Valuation & ratios

Valuation

as of 12/27/25
See full
Market cap$3.75B-4.3%
Enterprise value$4.61B-4.4%
P/E21.4×-8.8×
P/S2.8×0.0×

Profitability

See full
Gross margin59.4%+6.1pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin23.4%+16.2pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.3×0.0×
Current ratio1.7×-2.2×

Segments

By geography

See full
Other$1.8M-63.3%

By product

See full
Plasma$138.9M+3.5%

FAQ

When did Haemonetics report Q3 2026 earnings?
Haemonetics (HAE) reported Q3 2026 earnings on February 5, 2026 before market open.
What were Haemonetics's Q3 2026 revenue and EPS?
Haemonetics reported revenue of $339.0M and eps of $1.31 for Q3 2026.
Did Haemonetics beat estimates in Q3 2026?
Revenue beat the consensus estimate of $331.9M by $7.1M. EPS beat the consensus estimate of $1.27 by $0.04.
How did Haemonetics's Q3 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 2.7% from $348.5M a year earlier and eps grew 10.1% from $1.19.
Where can I find Haemonetics's Q3 2026 SEC filings?
You can read the 8-K earnings release (0000313143-26-000009) and the 10-Q periodic report (0000313143-26-000010) directly on SEC EDGAR. The filing index links above go to sec.gov.